- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Promotions and Additions for Pharmaceutical Executive and Pharmaceutical Commerce Editorial Teams
Restructural changes effective immediately.
The editorial teams of Pharmaceutical Executive and Pharmaceutical Commerce are excited to announce the following updates:
Mike Hollan (MHollan@mjhlifesciences.com) has been named editor of Pharmaceutical Executive, handling the technology and leadership columns, as well as general industry articles and interviews.
Meg Rivers (MRivers@mjhlifesciences.com) has been named managing editor of Pharmaceutical Executive and will be responsible for the day-to-day management and content direction of the brand. Formerly, Meg was the senior editor for our sister brands, Pharmaceutical Technology and BioPharm International, since June 2021. There, she interviewed industry leaders for print and online features, roundtables, and conferences, in addition to managing/co-hosting the biweekly Pharmaceutical Technology podcast, the Drug Solutions Podcast, as well as the Drug Digest video series.
Nico Saraceno (NSaraceno@mjhlifesciences.com) has been promoted to editor of Pharmaceutical Commerce. As associate editor since October 2020, Nico has successfully produced the Pharmaceutical Commerce podcast, taken on increasing responsibilities, and is now leading the day-to-day content management of the brand.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
